

**2021 Cardiology Pharmacy Specialty Recertification Literature Study:
Module 1B: Heart Failure/Cardiovascular Outcomes**

Learning Objectives and Articles

Module 1B: Heart Failure/Cardiovascular Outcomes

Universal Activity Number: 0204-9999-21-980-H01-P

Contact Hours: 4.00

Activity Type: Application-Based

This module focuses on cardiovascular outcomes with colchicine and empagliflozin, as well as new treatment options for heart failure.

Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. *N Engl J Med.* 2020; 383:1413-1424.

Learning Objectives:

- Describe the EMPEROR-Reduced study of empagliflozin in patients with heart failure with a reduced ejection fraction with or without type 2 diabetes mellitus
- Develop recommendations for the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with heart failure with a reduced ejection fraction with or without type 2 diabetes mellitus

Nidorf SM, Fiolet ATL, Msterd A, et al. Colchicine in patients with chronic coronary disease. *N Engl J Med.* 2020; 383:1838-1847.

Learning Objectives:

- Describe the LoDoCo2 study of colchicine in patients with chronic coronary disease
- Develop recommendations for the use of colchicine in patients with chronic coronary disease

Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. *N Engl J Med.* 2020; 382:1883-1893.

Learning Objectives:

- Describe the Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA) by Armstrong and colleagues
- Develop recommendations for the use of vericiguat in patients with worsening chronic heart failure and reduced ejection fraction

Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. *N Engl J Med.* 2019; 381:2497-505.

Learning Objectives:

- Describe the Colchicine Cardiovascular Outcomes Trial (COLCOT) by Tardif and colleagues of low-dose colchicine in patients with a recent myocardial infarction
- Develop recommendations for the use of low-dose colchicine in patients with a recent myocardial infarction

Teerlink JR, Diaz R, Felker GM, et al. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. *N Engl J Med.* 2021; 384(2):105-116

Learning Objectives:

- Describe the Global Approach to Lowering Adverse Cardiac Outcomes through Improving Contractility in Heart Failure (GALACTIC-HF) study by Teerlink and colleagues of omecamtiv mecarbil for heart failure with reduced ejection fraction
- Develop recommendations for the use of omecamtiv mecarbil in patients with heart failure and reduced ejection fraction